<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48642">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472977</url>
  </required_header>
  <id_info>
    <org_study_id>CA212-115</org_study_id>
    <secondary_id>2015-000136-15</secondary_id>
    <nct_id>NCT02472977</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors</brief_title>
  <acronym>CXCessoR4</acronym>
  <official_title>A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of Ulocuplumab and
      Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Intervention model: Single group for Stage 1 DLT, then Parallel

        -  Data Monitoring Committee: No (Stage 1) Yes (Stage 2 Randomized Ph2)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial terminated because of lack of efficacy in the short term acute phase.
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 27, 2017</completion_date>
  <primary_completion_date type="Actual">January 27, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLT) in the DLT evaluation period based on adverse events (AEs), Serious adverse events (SAEs) and laboratory abnormalities</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Tumor Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Tumor scans at pretreatment visit then every 6 weeks thereafter (up to 24 months)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>If a Phase 2 comparative study is initiated and, for PAC only: Overall Survival: time from randomization to date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety based on the incidence of DLT, AEs, SAEs and laboratory abnormalities</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Safety: DLT assessed during DLT evaluation period, AE/SAE assessed during study treatment and follow-up period (up to 24 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability based on the incidence of DLT, AEs, SAEs and laboratory abnormalities</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Tolerability: DLT assessed during DLT evaluation period, AE/SAE assessed during study treatment and follow-up period (up to 24 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival [(PFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Small cell lung cancer (SCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreatic cancer (PAC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulocuplumab</intervention_name>
    <arm_group_label>BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)</arm_group_label>
    <arm_group_label>BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)</arm_group_label>
    <other_name>BMS-936564</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)</arm_group_label>
    <arm_group_label>BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  SCLC or PAC that is advanced or has spread to other parts of the body

          -  Treated with at least one other chemotherapy that did not work or where cancer
             relapsed

          -  Minimal limitations on activities of daily living as measured by Eastern Cooperative
             Oncology Group (ECOG) score of 0-1

        Exclusion Criteria:

          -  Patients with cancer that spread to the brain

          -  Active, known or suspected autoimmune disease

          -  Prior treatment with any drug that targets T cell co-stimulation pathways (such as
             checkpoint inhibitors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>June 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
